Lung cancer protein study may unlock new clues

NCT ID NCT01647867

Completed Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined pieces of the Met receptor protein in tumor and healthy tissue from 56 people with non-small cell lung cancer. Researchers used blood and tissue samples taken during surgery or biopsy to see which Met fragments are present and whether they are active. The goal was to better understand how Met might be involved in lung cancer, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help identify new markers or targets for future lung cancer treatments.
What could go wrong: This is an observational study with no direct treatment, so it will not immediately benefit patients. Results may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Centre Hospitalier Régional et Universitaire

Lille, 59 037, France
Oscar Lambret Center

Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.